Journal of Translational Autoimmunity · Nov 2026
Convergence of Stem Cell Regeneration and Immunotherapy: A Systematic Review of Multisystem Therapeutic Advances in Cardiovascular, Musculoskeletal, and Immune Disease
By Sarma AD, Devi M, Kumar D et al.
The intersection between regenerative medicine and immunotherapy reflects the understanding that vascular remodeling and fibrotic resolution regulate tissue repair through inflammation, immune-cell phenotype, stromal signaling, and immune-cell immunophenotype. Stem cell therapies, such as mesenchymal stromal/stem cells (MSCs), hematopoietic cell transplantation (HCT), induced pluripotent stem cell (iPSC)-derived products, and extracellular vesicles (EVs), are now thought to be not only cell-replacement therapies but also immune-recalibrating therapies. This systematic review evidence was categorized into formally included clinical studies and contextual translational evidence. Clinical evidence synthesis focused on human intervention studies, while preclinical and mechanistic studies were used to interpret biological plausibility and translational pathways. The review followed PRISMA 2020 and PRISMA-S principles (PROSPERO registration number: CRD420261421270). PubMed/MEDLINE, Scopus, Web of Science, ScienceDirect, Embase, Cochrane Library, ClinicalTrials.gov , Google Scholar, and WHO ICTRP were used as information sources for studies published from 2008 to 2026. The screening process identified 1,243 records; 197 full reports were assessed for eligibility, and 11 human interventional clinical studies were included in the primary clinical evidence synthesis. Preclinical, mechanistic, and review-level studies were analysed separately as contextual translational evidence and were not counted among the 11 included clinical studies. The synthesis: Among the 11 included studies, MSC-based therapies demonstrated clinical response rates of 55–70% in steroid-refractory GVHD, while AHCT achieved sustained remission in selected autoimmune disorders. Among the included human clinical studies, hematopoietic cell transplantation approaches in selected autoimmune diseases and MSC-based therapies for steroid-refractory graft-versus-host disease demonstrated clinically meaningful signals; however, interpretation remains limited by differences in study design, sample size, comparators, follow-up duration, and intervention characteristic. Cardiovascular research shows plausible paracrine, angiogenic, and anti-inflammatory mechanisms but heterogeneous clinical effect sizes. Musculoskeletal evidence is most developed for knee osteoarthritis, where intra-articular MSC approaches may improve patient-reported outcomes in some trials. However, certainty remains limited by small samples, product heterogeneity, and variable comparators. MSC and EV effects are largely paracrine and immunomodulatory rather than dependent on durable engraftment. Major barriers include potency-assay standardization, donor variability, dose and route optimization, immune rejection, thrombosis, infection, tumourigenicity and incomplete long-term follow-up. Stem cell regeneration and immunotherapy represent an emerging regenerative-immunology framework; however, clinical translation remains dependent on standardized manufacturing, validated potency assays, biomarker-guided selection, larger controlled trials, and long-term safety surveillance. Future progress will depend on biomarker-guided patient selection, standardized manufacturing, and multicenter randomized clinical trials.
doi.org/10.1016/j.jtauto.2026.100411Open accessInterventions